- Trials with a EudraCT protocol (176)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
176 result(s) found for: Child-Pugh score.
Displaying page 1 of 9.
EudraCT Number: 2021-001235-12 | Sponsor Protocol Number: GULLIVER-2 | Start Date*: 2021-07-20 | |||||||||||
Sponsor Name:Galecto Biotech AB | |||||||||||||
Full Title: GULLIVER-2 - a single (open-label) and repeat dose (randomised, placebo-controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with he... | |||||||||||||
Medical condition: Healthy subjects (for study Parts 1 and 3) and patients with hepatic impairment (Child Pugh B and Child Pugh C) (cirrhosis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002567-42 | Sponsor Protocol Number: 5A | Start Date*: 2015-07-15 |
Sponsor Name:Stockholm County Council, Karolinska University Hospital Huddinge, Dept of Anesthesiology and Intensive Care | ||
Full Title: Predictors of albumin synthesis rate in severe liver failure. An open exploratory study in patients with chronic liver failure assessed for liver transplantation | ||
Medical condition: Severe chronic liver failure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-015785-64 | Sponsor Protocol Number: PRODIGE 11/FFCD 0803 | Start Date*: 2009-11-17 |
Sponsor Name:CHU de DIJON - Délégation à la recherche clinique et à l’innovation | ||
Full Title: ESSAI RANDOMISE - SORAFENIB-PRAVASTATINE VERSUS SORAFENIB SEUL POUR LE TRAITEMENT PALLIATIF DU CARCINOME HEPATOCELLULAIRE CHILD-PUGH A | ||
Medical condition: Carcinome hépatocellulaire (CHC) non accessible à un traitement à visée curative | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) BE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002079-16 | Sponsor Protocol Number: E2013_PK_CASPO70_LIVERFAILURE | Start Date*: 2013-09-05 | |||||||||||
Sponsor Name:Hospital Erasme | |||||||||||||
Full Title: Pharmacokinetics of Caspofungin after one dose in patients with liver failure. | |||||||||||||
Medical condition: The pharmacokinetics parameters of caspofungin will be studied for the patient admitted for alcoholic hepatitis or decompensated cirrhosis (Child-Pugh score 7-15). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004371-22 | Sponsor Protocol Number: ADN009 | Start Date*: 2015-01-12 | |||||||||||
Sponsor Name:ADIENNE SA | |||||||||||||
Full Title: Phase IV study to assess, the effect of hepatic impairment on the pharmacokinetics of Thiotepa and the potential of Thiotepa to alter the QT interval in pedatric patients undergoing allogeneic haem... | |||||||||||||
Medical condition: Patients with various hematological disease requiring Bone Marrow Transplantation, with Child-Pugh score A and B | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008232-87 | Sponsor Protocol Number: SOCS-B | Start Date*: 2009-04-03 | |||||||||||
Sponsor Name:Charite Universitätsmedizin Berlin- Campus Virchow-Klinikum | |||||||||||||
Full Title: Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older | |||||||||||||
Medical condition: hepatocellular carcinoma and Child Pugh score B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003108-15 | Sponsor Protocol Number: UC-GIG-2003 | Start Date*: 2022-11-04 | |||||||||||
Sponsor Name:UNICANCER | |||||||||||||
Full Title: A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function Score | |||||||||||||
Medical condition: Hepatocellular Carcinoma (HCC), Child-Pugh B, ALBI grade 1 or 2 liver function | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004031-23 | Sponsor Protocol Number: E2012AILIVER | Start Date*: 2014-08-26 | |||||||||||
Sponsor Name:Hopital Erasme | |||||||||||||
Full Title: Serum pharmacokinetics of Caspofungin in patients with liver failure. | |||||||||||||
Medical condition: The patient admitted for alcoholic hepatitis or decompensated cirrhosis (Child-Pugh score of 10-15) presenting with invasive aspergillosis (proven or probable) and treated by caspofungin. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001139-22 | Sponsor Protocol Number: POPH | Start Date*: 2011-06-29 | |||||||||||
Sponsor Name:Medizinische Universität Graz, Klin. Abteilung für Gastroenterologie und Hepatologie | |||||||||||||
Full Title: AMBRISENTAN FOR TREATMENT OF PORTOPULMONARY HYPERTENSION (POPH): A PILOT STUDY | |||||||||||||
Medical condition: Portopulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome HPS are present in a considerable number of patients with compensated cirrhosis. Treatment of PoPH with ambrisentan is well tolerated... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021590-37 | Sponsor Protocol Number: A4061058 | Start Date*: 2011-01-03 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017,USA | |||||||||||||
Full Title: A MULTICENTER, GLOBAL, RANDOMIZED, DOUBLE-BLIND STUDY OF AXITINIB PLUS BEST SUPPORTIVE CARE VERSUS PLACEBO PLUS BEST SUPPORTIVE CARE IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA FOLLOWING FAI... | |||||||||||||
Medical condition: Hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) SK (Completed) GB (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002053-30 | Sponsor Protocol Number: EMR200095-005 | Start Date*: 2014-05-16 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects with MET+ Advanced Hepatocellular Carcinoma with Child Pugh Class A Liv... | |||||||||||||
Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002088-25 | Sponsor Protocol Number: N-003-CRD003 | Start Date*: 2019-01-11 | |||||||||||
Sponsor Name:Noorik Biopharmaceuticals AG | |||||||||||||
Full Title: A Phase II, Single-arm, Open-Label Study to Characterise the Effect on Portal Pressure, the Effect on Renal Function and the Pharmacokinetic Profile of N-003 in Patients with Decompensated Cirrhosis | |||||||||||||
Medical condition: decompensated liver cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011925-14 | Sponsor Protocol Number: 1199.37 | Start Date*: 2009-08-24 | |||||||||||
Sponsor Name:Boehringer Ingelheim | |||||||||||||
Full Title: A multicenter, open label, phase I / II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients. | |||||||||||||
Medical condition: Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 7 or less, in 1st lin... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) AT (Completed) DE (Completed) SK (Completed) HU (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019318-26 | Sponsor Protocol Number: IMCL_CP12-0919_(I4T-IE-JVBF) | Start Date*: 2010-09-27 | |||||||||||
Sponsor Name:ImClone LLC | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepato... | |||||||||||||
Medical condition: Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) CZ (Completed) PT (Completed) BE (Completed) ES (Completed) AT (Completed) FR (Completed) BG (Completed) HU (Completed) IT (Completed) SE (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001075-36 | Sponsor Protocol Number: CaboCHILD | Start Date*: 2020-04-20 |
Sponsor Name:Universitätsmedizin Mainz | ||
Full Title: A phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib in patients with hepatocellular carcinoma (HCC) and impaired liver function (Child-Pugh score B7-8) - CABOCHILD - | ||
Medical condition: Hepatocellular carcinoma (HCC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004728-39 | Sponsor Protocol Number: AURORA | Start Date*: 2020-07-31 |
Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest | ||
Full Title: A Phase II, non-randomized, single arm, translational study of CAbozantinib for Patients with HepatocellUlaR CarcinOma (HCC) Refractory to first line TreAtment | ||
Medical condition: Locally advanced or metastatic and/or unresectable HCC | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003925-17 | Sponsor Protocol Number: HCC-PBMC-GM-CSF | Start Date*: 2008-10-20 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI PARMA | |||||||||||||
Full Title: Immunotherapy by autologous peripheral blood mononuclear cells and GM-CSF for hepatocellular carcinoma undergoing radiofrequency thermal ablation | |||||||||||||
Medical condition: patients with hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003557-27 | Sponsor Protocol Number: SA-388-4-1 | Start Date*: Information not available in EudraCT |
Sponsor Name:Dean of the Medical Faculty (University of Bonn) | ||
Full Title: Covered Transjugular Intrahepatic Portosystemic Stent Shunt versus Optimized medical Treatment for the Secondary Prevention of Variceal Bleeding in Cirrhosis | ||
Medical condition: liver cirrhosis; esophageal (variceal) bleeding | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004060-70 | Sponsor Protocol Number: GESIDA-4304 | Start Date*: 2005-01-25 |
Sponsor Name:Juan Gonzalez García | ||
Full Title: Pilot study randomised and open to compare the switch to trizivir against the previous treatment in chronic HIV-1 infected patients with liver cirrhosis secondary to Hepatitis C coinfection | ||
Medical condition: Antiviral treatment of HIV-1 infected patients with liver cirrhosis secondary to Hepatitis C coinfection. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004713-24 | Sponsor Protocol Number: GECOMstudy | Start Date*: 2016-04-11 | ||||||||||||||||
Sponsor Name:IRCCS ISTITUTO CLINICO HUMANITAS | ||||||||||||||||||
Full Title: A Multicenter, Open Label, Pilot Study to Investigate Tolerability and Efficacy of MK5172 (Grazoprevir) / MK8742 (Elbasvir) Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection... | ||||||||||||||||||
Medical condition: Chronic infection with Hepatitis C virus genotype 1b with compensated cirrhosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
